In 2023, Eli Lilly and reported a 20% increase in revenue, reaching $34,124.1 million compared to $28,541.4 million in 2022. This growth was driven by increased volume and higher realized prices, primarily from sales of Mounjaro®, Verzenio®, and Jardiance®, as well as the sales of the rights for the olanzapine portfolio, including Zyprexa®, and for Baqsimi®. However, this was partially offset by the absence of revenue from COVID-19 antibodies and lower sales of Alimta® following the entry of multiple generics in the first half of 2022.
Despite the increase in revenue, net income and earnings per share both decreased by 16% in 2023. This was primarily due to higher acquired in-process research and development (IPR&D) charges and increased research and development expenses, marketing, selling, and administrative expenses, and income taxes.
Eli Lilly and's long-term success depends on its ability to continually discover or acquire, develop, and commercialize innovative medicines. The company currently has approximately 50 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.
The company's late-stage pipeline includes various select new molecular entities (NMEs) and new indication line extension (NILEX) products currently in Phase II or Phase III clinical trials or have been submitted for regulatory review or have recently received regulatory approval in the U.S., European Union (EU), or Japan. These developments are crucial for the company's future growth and success.
However, the pharmaceutical industry is inherently challenging and uncertain. There is a high rate of failure in drug discovery and development, and bringing a product from the discovery phase to market takes considerable time and entails significant cost. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications, leading to delays and unpredictability in drug approval processes across markets and agencies.
Eli Lilly and also highlighted the impact of the Inflation Reduction Act of 2022 (IRA) on its business. The IRA requires the U.S. Department of Health and Human Services (HHS) to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. This law has and will meaningfully influence the company's business strategies and those of its competitors, potentially impacting revenue and business operations.
In addition, global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. These measures include the use of mandated discounts, price reporting requirements, restrictive formularies, and changes to available intellectual property protections, which could significantly impact Eli Lilly and's business and consolidated results of operations.
In summary, while Eli Lilly and reported an increase in revenue, the company faces challenges and uncertainties in its late-stage pipeline developments, as well as potential impacts from regulatory changes and cost containment efforts in the pharmaceutical industry. As a result of these announcements, the company's shares have moved -1.7% on the market, and are now trading at a price of $742.53. For more information, read the company's full 10-K submission here.
